Endocrine Abstracts

Introduction: Glucose metabolism impairment is a common complication of acromegaly. Somatostatin analogs (SSAs) are used as both first and second line treatment. The effect of SSAs on glucose metabolism in acromegaly is still debated.Aim: To address the following questions: 1) do SSAs affect glucose metabolism? 2) does the effect correlate with disease control? 3) do different SSAs – Lanreotide (LAN) and octreotide LAR (OCT) – affect metabolism...

Introduction: Glucose metabolism impairment is a common complication of acromegaly. Pegvisomant (PEG) is used as second-line medical treatment in acromegaly. Data from literature suggest a positive effect of PEG on glucose metabolism but a meta-analysis has never been performed.Aim: To address the following questions: i) does PEG affect glucose metabolism? ii) does the effect correlate with disease control?Methods: We performed a m...

Background: Cyclic GMP-phosphodiesterase type 5(PDE5) inhibition was shown to counteract maladaptive cardiac changes triggered by diabetes in some, but not all studies.Objective: To assess sex differences in cardiac remodeling after PDE5 inhibition in patients with diabetic cardiomyopathy.Methods: 20-week, double-blind, randomized, placebo-controlled trial (NCT01803828). 220 men and women (45-80 years) with long-duration (>3 ye...